Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

203 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE:

* Elevation in pulsatility indices (PIs), measured by transcranial Doppler (TCD), has been postulated to reflect downstream increased vascular resistance caused by small-vessel disease (SVD).
* Small arterial vessels are a significant determinant of vascular resistance and PIs are elevated when SVD is present in the intracranial circulation.
* Cilostazol, a phosphodiesterase III inhibitor, has other non-antiplatelet effects, such as vasodilation and neuroprotective effect. It has been shown to be effective in the secondary prevention of stroke especially in the SVD and it may be related to the other non-antiplatelet effects of cilostazol.

OBJECTIVES:

* In this study, we aim to investigate whether cilostazol affects the changes of PIs in patients with acute lacunar infarction using serial TCDs.
* Our hypothesis is that cilostazol has other non-antiplatelet effects such as vasodilation effect and may decrease the vascular resistance in patients with acute lacunar infarction. Hence, cilostazol will decrease the PIs in patients with acute lacunar infarction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

NCT01932203

Cerebral Small Vessel Disease

UNKNOWN PHASE4

Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

NCT00446641

Cerebral Infarction

COMPLETED PHASE4

The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients

NCT03116269

Ischemic Stroke Endothelial Dysfunction

COMPLETED PHASE4

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

NCT00130039

Cerebral Infarction Atherosclerosis

COMPLETED PHASE4

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

NCT00272454

Cerebral Infarction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TREATMENTS:

* Cilostazol is an agent inhibiting platelet aggregation.
* A matching placebo of cilostazol is an inactive substance that looks similar to the active cilostazol tablet.

TREATMENT PLAN:

* There will be two treatment groups; one will receive cilostazol 200mg (100mg twice per day), the second matching placebo of cilostazol.
* These study drugs will be administered on top of aspirin (100mg) systematically prescribed to such patients

PRIMARY ENDPOINT:

* The changes of PI between the baseline and 14 and 90 days follow-up study.

STUDY EXECUTION:

* Two hundred sixty patients, presenting with first ever lacunar infarction within 7 days after the onset of symptoms will be recruited within two years.
* Patients will be followed up during the three months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asprin (100mg) plus placebo

Group Type PLACEBO_COMPARATOR

Aspirin

Intervention Type DRUG

Asprin (100mg) plus placebo

Asprin (100mg) plus cilostazol (200mg)

Group Type ACTIVE_COMPARATOR

cilostazol

Intervention Type DRUG

Aspirin (100mg) plus cilostazol (200mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aspirin

Asprin (100mg) plus placebo

Intervention Type DRUG

cilostazol

Aspirin (100mg) plus cilostazol (200mg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pletaal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with first ever lacunar infarction within 7 days after the onset of symptoms
* Age: more than 45 years of age

Exclusion Criteria

* Patients with any contraindications to the treatment with antiplatelet therapy
* Patients with potential cardiac embolic source; prosthetic valve, atrial fibrillation, atrial flutter, left atrial/atrial appendage thrombus, sick sinus syndrome, left ventricular thrombus, dilated cardiomyopathy, akinetic or hypokinetic left ventricular segment, atrial myxoma, Infective endocarditis, mitral valve stenosis or prolapse, mitral annuls calcification, left atrial turbulence, nonbacterial endocarditis, congestive heart failure, recent myocardial infarction (within 4 weeks)
* Bleeding diathesis
* Chronic liver disease (ALT \> 100 or AST \> 100) or chronic renal disease (creatinine \> 3.0mg/dl)
* Anemia (hemoglobin \< 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)
* Nonatherosclerotic vasculopathy; patients with clinical characteristics suggesting arterial dissection, moyamoya disease, Takayasu's arteritis, radiation associated angiopathy, and other vasculitis.
* Pregnant or lactating patients
* Patients with hyperthyroidism or COPD
* Patients with current anticoagulation or antiplatelet therapy
* Patients with poor temporal window in transcranial Doppler

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No